Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Esketamine is not a breakthrough new drug: Why the nasal spray for depression is old news

Erik Messamore, MD, PhD
Meds
March 6, 2019
7K Shares
Share
Tweet
Share

The FDA has given official approval to market eskatamine as a treatment for depression. As expected, there has been great fanfare (press releases, morning TV talk show guests, NPR segments and so on). The news leaves me salty. The esketamine story reveals so much of what is wrong about how we get useful medical science findings into clinical practice.

Esketamine is not a new drug

Esketamine is being promoted as a new drug, as a breakthrough new drug. It’s not.

Drugs are complex molecules and complex molecules can have both right-handed and left-handed forms. Same chemical formula – just mirror-image forms. That’s how nature rolls.

Esketamine is the left-handed subtype of the very old, very cheap, and very generically-available drug ketamine.

It’s not a new drug. It’s just the left half of what the old drug used to be.

Using ketamine or esketamine to treat depression is not a breakthrough discovery

This part that chafes me the most. We’ve known since at least 2006 that ketamine (old, cheap, generic ketamine) rapidly shrink depressive symptoms. The antidepressant response occurs in a matter of hours and can last for up to a week after a single dose.

This fact has been in the medical literature for about 13 years.

There is a 10 percent suicide rate in severe depression. And about half of patients with depression don’t respond to first-line treatments.

There was an urgent (literally life-or-death) need to move generic ketamine into clinical practice. For 13 years, we could have been offering this treatment at scale, saving lives in the process.

The fact that we couldn’t do this speaks volumes.

We didn’t need eskatamine, really

We just needed a way to get 2006 medical science discoveries into clinical practice in less than 13 years.

Why most patients couldn’t get ketamine for depression

I actually wanted to offer ketamine to my severely depressed and not-medication-responding patients. So, I called my professional liability insurance carrier. They told me: No way.

Absent FDA approval, they said, they would not stand by me if something bad happened.

Even if I were to take the risk of practicing without liability insurance, my patients’ insurance would not pay for it. Patients would have to pay out of pocket.

Also, most doctors were not aware of the ketamine story for many years. The ketamine data were published in the kinds of journals that most doctors don’t read.

Professional organizations like the American Psychiatric Association could have disseminated the ketamine story. They could even have lobbied to get insurance companies to cover the treatment and indemnify the clinicians. But nothing happened.

The easy work of developing eskatamine

Even though eskatamine is really just the left-handed half of ordinary ketamine, U.S. patent law allows for eskatmine to be patented.

With patent protection, Janssen Pharmaceuticals could then run the clinical trials necessary to get FDA approval.

From the company’s point of view, this was a triple win. First, they didn’t have to invent a drug. Ketamine was already there. Second, they didn’t have to spend a bunch of money on effectiveness discovery. We already knew that ketamine works and esketamine is really just ketamine. Finally, because of this, success in clinical trials was guaranteed.

So now, Janssen can sell a drug that’s very cheap to manufacture for about $800 per dose.

As a business move, this is brilliant.

As a story about how to quickly move treatments from science to the clinic, it reveals a problem.

Why did it take esketamine to get people to take seriously the use of ketamine for depression?

This is how medicine works in the modern era.

  • Without FDA approval, insurance companies will find a convenient excuse not to cover treatments – even if medical science shows that the treatment is useful.
  • Only pharmaceutical companies have enough money to get the FDA to look at data and opine on effectiveness.
  • Pharmaceutical companies won’t spend a dime to ask the FDA to review generic drugs like ketamine (or natural products like fish oil)
  • We do not have organizations are reliably willing to review non-industry-sponsored science and make recommendations about when a generic drug or natural product should move into clinical practice.

I find this situation tragic because the medical literature is jam-packed with discoveries that can solve clinical problems (often at low cost). Yet it’s a steep uphill battle to get this knowledge into clinical practice.

We sorely need to set up commissions that can review existing data and make FDA-like recommendations about on off-label use of generic drugs and natural products. You would be surprised how many diseases could be better treated if we were to create this kind of process. It shouldn’t take 13 years to get the next treatment from the clinical science journal into clinical service.

Erik Messamore is a psychiatrist and can be reached on Twitter @ErikMessamoreMD and LinkedIn.

Image credit: Shutterstock.com

Prev

After Luke Perry: a greater awareness of stroke symptoms

March 6, 2019 Kevin 1
…
Next

How telemedicine can help patients and solve physician burnout

March 6, 2019 Kevin 2
…

Tagged as: Medications, Psychiatry

Post navigation

< Previous Post
After Luke Perry: a greater awareness of stroke symptoms
Next Post >
How telemedicine can help patients and solve physician burnout

More by Erik Messamore, MD, PhD

  • Many medical marijuana program websites are silent about possible risks

    Erik Messamore, MD, PhD
  • It’s time to pay people to self-quarantine

    Erik Messamore, MD, PhD
  • America has seen medical marijuana before: This is what we learned (and forgot)

    Erik Messamore, MD, PhD

Related Posts

  • Are negative news cycles and social media injurious to our health?

    Rabia Jalal, MD
  • Treating depression with ketamine: We need incremental treatment for depression

    Shaili Jain, MD
  • How hospitals can impact generic drug companies

    Mark Kelley, MD
  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • Drug ads are a campaign against physician trust

    Judy Salz, MD
  • Crippling drug costs: the role of insurers

    Janice Boughton, MD

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Nose-brain connection: The surprising link between allergies and mental health revealed

      Kara Wada, MD | Conditions
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • Urgent innovation needed to address growing mental health crisis among children and families

      Monika Roots, MD | Conditions
    • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

      Cheryl Lazarus | Conditions
    • Medical errors and the power of apologies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding your ideal work-life balance: tips for prioritizing personal life and achieving professional success

      Zahid Awan, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • 7 ways to beat burnout: a guide for health care professionals to reduce stress and reclaim their passion

      Marie Livesey, DO | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Trial Shows RA Can Be Stopped at Preclinical Stage
  • Study Suggests Increase in Brain Aging in Those With Type 1 Diabetes
  • How to Set Up Your Referral Network
  • Missing Doctor's Gunshot Wound; COVID Funds Reshuffled; Helpline Chatbot Shut Down
  • Second RSV Vaccine Lands Approval for Older Adults

Meeting Coverage

  • Trial Shows RA Can Be Stopped at Preclinical Stage
  • Tenapanor Improves Abdominal Symptoms in Patients With IBS-C
  • Benefits Found for Hand OA Drug Treatments
  • MRI-Based Screening May Detect Prostate Cancer Earlier
  • New Model Aims to Study Intestinal Fibrosis in Crohn's Disease
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Nose-brain connection: The surprising link between allergies and mental health revealed

      Kara Wada, MD | Conditions
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • Urgent innovation needed to address growing mental health crisis among children and families

      Monika Roots, MD | Conditions
    • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

      Cheryl Lazarus | Conditions
    • Medical errors and the power of apologies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding your ideal work-life balance: tips for prioritizing personal life and achieving professional success

      Zahid Awan, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • 7 ways to beat burnout: a guide for health care professionals to reduce stress and reclaim their passion

      Marie Livesey, DO | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Esketamine is not a breakthrough new drug: Why the nasal spray for depression is old news
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...